Cover Image
市場調查報告書

全身性紅斑性狼瘡 (SLE):開發中產品分析

Systemic Lupus Erythematosus - Pipeline Review, H2 2017

出版商 Global Markets Direct 商品編碼 264101
出版日期 內容資訊 英文 427 Pages
訂單完成後即時交付
價格
Back to Top
全身性紅斑性狼瘡 (SLE):開發中產品分析 Systemic Lupus Erythematosus - Pipeline Review, H2 2017
出版日期: 2017年11月14日 內容資訊: 英文 427 Pages
簡介

全身性紅斑性狼瘡 (SLE) ,是造成長期慢性發炎性疾病的自體免疫疾病。SLE引發的發炎會影響皮膚和關節、腎臟、腦等器官。發病的各式因素與遺傳、環境、性、荷爾蒙等疾病有關。症侯有很多種,隨時間變化,不過,一般有嚴重的疲勞感、關節的疼痛和腫、頭痛、稱作蝶形紅斑的臉頰和鼻子的皮疹、掉頭髮、貧血等。

本報告提供全身性紅斑性狼瘡 (SLE)的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您夾雜最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃相關資訊等資訊。

簡介

  • 調查範圍

全身性紅斑性狼瘡概要

治療藥的開發

治療藥的評估

開發治療藥的企業

藥物簡介

暫停中的計劃

開發中止的產品

產品開發的里程碑

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9879IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides an overview of the Systemic Lupus Erythematosus (Immunology) pipeline landscape.

Systemic lupus erythematosus (SLE) is an autoimmune disease that causes a chronic inflammatory condition. The inflammation triggered by SLE affect many organs in the body, including skin, joints, kidneys, brain, and other organs. Several factors have been associated with the disease such as genetics, environment and gender and hormones. Symptoms can vary and can change over time. Common symptoms include severe fatigue, painful or swollen joints, headaches, rash on cheeks and nose called butterfly rash, hair loss and anemia.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Systemic Lupus Erythematosus - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Systemic Lupus Erythematosus (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Systemic Lupus Erythematosus (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Lupus Erythematosus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 6, 28, 25, 40, 4 and 3 respectively. Similarly, the Universities portfolio in Phase II, IND/CTA Filed, Preclinical and Discovery stages comprises 1, 1, 9 and 1 molecules, respectively.

Systemic Lupus Erythematosus (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Lupus Erythematosus (Immunology).
  • The pipeline guide reviews pipeline therapeutics for Systemic Lupus Erythematosus (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Systemic Lupus Erythematosus (Immunology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Systemic Lupus Erythematosus (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Lupus Erythematosus (Immunology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Systemic Lupus Erythematosus (Immunology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Systemic Lupus Erythematosus (Immunology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents 2
  • List of Tables 7
  • List of Figures 9
  • Introduction 10
  • Global Markets Direct Report Coverage 10
  • Systemic Lupus Erythematosus - Overview 11
  • Systemic Lupus Erythematosus - Therapeutics Development 12
  • Pipeline Overview 12
  • Pipeline by Companies 13
  • Pipeline by Universities/Institutes 19
  • Products under Development by Companies 20
  • Products under Development by Universities/Institutes 27
  • Systemic Lupus Erythematosus - Therapeutics Assessment 28
  • Assessment by Target 28
  • Assessment by Mechanism of Action 33
  • Assessment by Route of Administration 38
  • Assessment by Molecule Type 40
  • Systemic Lupus Erythematosus - Companies Involved in Therapeutics Development 42
  • AbbVie Inc 42
  • Ablynx NV 42
  • ACEA Biosciences Inc 43
  • AiCuris GmbH & Co KG 43
  • Amgen Inc 43
  • Asahi Kasei Pharma Corp 44
  • Atlantic Bio Sci LLC 44
  • Aurinia Pharmaceuticals Inc 45
  • Bio-Path Holdings Inc 45
  • Biogen Inc 46
  • Biotest AG 46
  • Boehringer Ingelheim GmbH 47
  • Bristol-Myers Squibb Co 47
  • Celgene Corp 48
  • Corestem Inc 48
  • CuraVac Inc 49
  • Deltanoid Pharmaceuticals Inc 49
  • Domainex Ltd 50
  • Eisai Co Ltd 50
  • Eli Lilly and Co 50
  • F. Hoffmann-La Roche Ltd 51
  • Galapagos NV 51
  • Genentech Inc 52
  • Genosco Inc 52
  • Genovax Srl 53
  • Gilead Sciences Inc 53
  • GlaxoSmithKline Plc 54
  • HanAll Biopharma Co Ltd 54
  • Hanmi Pharmaceuticals Co Ltd 55
  • Idorsia Ltd 55
  • Immungenetics AG 55
  • Immunomedics Inc 56
  • Immunwork Inc 56
  • Immupharma Plc 57
  • Invion Ltd 57
  • Janus Biotherapeutics Inc 58
  • Johnson & Johnson 58
  • K-Stemcell Co Ltd 59
  • Karyopharm Therapeutics Inc 59
  • KPI Therapeutics Inc 59
  • Kyowa Hakko Kirin Co Ltd 60
  • Lead Discovery Center GmbH 60
  • LSK BioPartners Inc 61
  • MacroGenics Inc 61
  • MedAnnex Ltd 62
  • Medestea Research & Production SpA 62
  • MedImmune LLC 62
  • Merck & Co Inc 63
  • Merck KGaA 63
  • Millennium Pharmaceuticals Inc 64
  • Mitsubishi Tanabe Pharma Corp 64
  • Mount Tam Biotechnologies Inc 65
  • Nektar Therapeutics 65
  • Neovacs SA 66
  • Nippon Chemiphar Co Ltd 66
  • Novartis AG 67
  • Nuevolution AB 67
  • Omeros Corp 68
  • Pfizer Inc 68
  • Principia Biopharma Inc 69
  • Ra Pharmaceuticals Inc 69
  • RedHill Biopharma Ltd 70
  • Sarepta Therapeutics Inc 70
  • SBI Biotech Co Ltd 71
  • Takeda Pharmaceutical Co Ltd 71
  • TheraMAB LLC 71
  • TxCell SA 72
  • UCB SA 72
  • Xencor Inc 73
  • XTL Biopharmaceuticals Ltd 73
  • Zai Lab Ltd 73
  • Systemic Lupus Erythematosus - Drug Profiles 75
  • (clarithromycin + clofazimine + rifabutin) - Drug Profile 75
  • abatacept - Drug Profile 85
  • ABS-11 - Drug Profile 94
  • AC-058 - Drug Profile 95
  • ACY-1083 - Drug Profile 96
  • ACY-738 - Drug Profile 97
  • aldesleukin - Drug Profile 99
  • aldesleukin - Drug Profile 100
  • AMG-557 - Drug Profile 101
  • AMG-570 - Drug Profile 103
  • amiselimod hydrochloride - Drug Profile 104
  • anifrolumab - Drug Profile 106
  • Annexuzlimab - Drug Profile 109
  • Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 110
  • APT-602 - Drug Profile 111
  • AT-791 - Drug Profile 112
  • atacicept - Drug Profile 113
  • baricitinib - Drug Profile 116
  • bee venom [Apis mellifera] allergen extract - Drug Profile 128
  • belimumab - Drug Profile 129
  • belimumab + rituximab - Drug Profile 137
  • BI-655064 - Drug Profile 138
  • BI-705564 - Drug Profile 140
  • BIIB-059 - Drug Profile 141
  • BIIB-068 - Drug Profile 142
  • Bispecific Monoclonal Antibody to Inhibit CD22 and CD20 for Autoimmune Disorders and Oncology - Drug Profile 143
  • BL-5923 - Drug Profile 144
  • BMS-986165 - Drug Profile 145
  • bortezomib - Drug Profile 147
  • BT-063 - Drug Profile 155
  • C-15231A - Drug Profile 156
  • CC-90008 - Drug Profile 158
  • Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 159
  • Cellular Immunotherapy for Epstein-Barr Viral Infections, Multiple Sclerosis and Systemic Lupus Erythematosus - Drug Profile 161
  • Cellular Immunotherapy to Target CD19 for Oncology and Immunology - Drug Profile 162
  • cenerimod - Drug Profile 163
  • CS-20AT04 - Drug Profile 165
  • dalazatide - Drug Profile 166
  • dapirolizumab pegol - Drug Profile 171
  • DMXD-011 - Drug Profile 173
  • DP-001 - Drug Profile 175
  • Drug to Antagonize Bradykinin Receptor B1 for Lupus Nephritis - Drug Profile 177
  • Drugs to Inhibit BAFF and APRIL for Systemic Lupus Erythematosus - Drug Profile 178
  • E-6446 - Drug Profile 179
  • edratide - Drug Profile 180
  • ENTX-LN - Drug Profile 183
  • evobrutinib - Drug Profile 184
  • faralimomab - Drug Profile 186
  • filgotinib - Drug Profile 187
  • forigerimod acetate - Drug Profile 200
  • GDC-0853 - Drug Profile 204
  • GNKS-356 - Drug Profile 206
  • GS-9876 - Drug Profile 207
  • GX-101 - Drug Profile 209
  • HCI-1401 - Drug Profile 210
  • HE-33 - Drug Profile 211
  • HL-161 - Drug Profile 212
  • iberdomide hydrochloride - Drug Profile 213
  • ICP-022 - Drug Profile 216
  • IL-233 - Drug Profile 217
  • IMP-10 - Drug Profile 218
  • INV-103 - Drug Profile 219
  • INV-17 - Drug Profile 222
  • INV-88 - Drug Profile 223
  • ixazomib citrate - Drug Profile 224
  • JB-6121 - Drug Profile 235
  • JNJ-0839 - Drug Profile 236
  • JNJ-56022473 - Drug Profile 237
  • KPT-350 - Drug Profile 239
  • lenabasum - Drug Profile 241
  • lulizumab pegol - Drug Profile 250
  • MEDI-7734 - Drug Profile 251
  • MGD-010 - Drug Profile 252
  • milatuzumab - Drug Profile 255
  • mizoribine - Drug Profile 258
  • NC-2400 - Drug Profile 259
  • NCS-613 - Drug Profile 260
  • NKTR-358 - Drug Profile 261
  • NUE-7770 - Drug Profile 263
  • obinutuzumab - Drug Profile 265
  • OMS-721 - Drug Profile 274
  • P-Dex - Drug Profile 284
  • PF-06823859 - Drug Profile 285
  • poseltinib - Drug Profile 286
  • prexigebersen - Drug Profile 288
  • PRN-1008 - Drug Profile 295
  • RA-101495 - Drug Profile 297
  • RCT-18 - Drug Profile 300
  • RSLV-132 - Drug Profile 301
  • RSLV-133 - Drug Profile 303
  • SBI-9674 - Drug Profile 304
  • SKIO-703 - Drug Profile 305
  • SM-03 - Drug Profile 307
  • SM-934 - Drug Profile 308
  • Small Molecule to Agonize CD11b for Systemic Lupus Erythematosus - Drug Profile 309
  • Small Molecule to Inhibit NFkB for Ophthalmology, Oncology and Immunology - Drug Profile 310
  • Small Molecules for Dermatology, Immunology, Metabolic and CNS Disorders - Drug Profile 311
  • Small Molecules for Respiratory and Immunology - Drug Profile 312
  • Small Molecules to Inhibit NET Formation for Sepsis and SLE - Drug Profile 313
  • Small molecules to Inhibit PAD for Autoimmune Diseases, Multiple Sclerosis and Oncology - Drug Profile 314
  • Stem Cell Therapy for Musculoskeletal, CNS Disorders, Dermatology, Immunology, Oncology and Cardiovascular Disease - Drug Profile 316
  • Synthetic Peptide to Inhibit Complement C5 for Autoimmune Disorders, Atypical Hemolytic Uremic Syndrome, Central Nervous System and Paroxysmal Nocturnal Hemoglobinuria - Drug Profile 318
  • Synthetic Peptides for Systemic Lupus Erythematosus - Drug Profile 319
  • TAB-08 - Drug Profile 320
  • TAK-079 - Drug Profile 323
  • TAM-01 - Drug Profile 324
  • TE-2324 - Drug Profile 326
  • tofacitinib citrate - Drug Profile 327
  • ustekinumab - Drug Profile 345
  • Vaccine for Systemic Lupus Erythematosus - Drug Profile 352
  • Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile 353
  • venetoclax - Drug Profile 359
  • VISTA-Ig - Drug Profile 373
  • vobarilizumab - Drug Profile 374
  • voclosporin - Drug Profile 380
  • WITH-1101 - Drug Profile 391
  • XL-499 - Drug Profile 392
  • XmAb-5871 - Drug Profile 393
  • ZL-1101 - Drug Profile 397
  • Systemic Lupus Erythematosus - Dormant Projects 398
  • Systemic Lupus Erythematosus - Discontinued Products 404
  • Systemic Lupus Erythematosus - Product Development Milestones 406
  • Featured News & Press Releases 406
  • Appendix 418
  • Methodology 418
  • Coverage 418
  • Secondary Research 418
  • Primary Research 418
  • Expert Panel Validation 418
  • Contact Us 418
  • Disclaimer 419

List of Tables

  • Number of Products under Development for Systemic Lupus Erythematosus, H2 2017 20
  • Number of Products under Development by Companies, H2 2017 22
  • Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 23
  • Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 24
  • Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 25
  • Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 26
  • Number of Products under Development by Universities/Institutes, H2 2017 27
  • Products under Development by Companies, H2 2017 28
  • Products under Development by Companies, H2 2017 (Contd..1), H2 2017 29
  • Products under Development by Companies, H2 2017 (Contd..2), H2 2017 30
  • Products under Development by Companies, H2 2017 (Contd..3), H2 2017 31
  • Products under Development by Companies, H2 2017 (Contd..4), H2 2017 32
  • Products under Development by Companies, H2 2017 (Contd..5), H2 2017 33
  • Products under Development by Companies, H2 2017 (Contd..6), H2 2017 34
  • Products under Development by Universities/Institutes, H2 2017 35
  • Number of Products by Stage and Target, H2 2017 37
  • Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 38
  • Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 39
  • Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 40
  • Number of Products by Stage and Mechanism of Action, H2 2017 42
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 43
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 44
  • Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 45
  • Number of Products by Stage and Route of Administration, H2 2017 47
  • Number of Products by Stage and Molecule Type, H2 2017 49
  • Systemic Lupus Erythematosus - Pipeline by AbbVie Inc, H2 2017 50
  • Systemic Lupus Erythematosus - Pipeline by Ablynx NV, H2 2017 51
  • Systemic Lupus Erythematosus - Pipeline by ACEA Biosciences Inc, H2 2017 51
  • Systemic Lupus Erythematosus - Pipeline by AiCuris GmbH & Co KG, H2 2017 51
  • Systemic Lupus Erythematosus - Pipeline by Amgen Inc, H2 2017 52
  • Systemic Lupus Erythematosus - Pipeline by Asahi Kasei Pharma Corp, H2 2017 52
  • Systemic Lupus Erythematosus - Pipeline by Atlantic Bio Sci LLC, H2 2017 53
  • Systemic Lupus Erythematosus - Pipeline by Aurinia Pharmaceuticals Inc, H2 2017 53
  • Systemic Lupus Erythematosus - Pipeline by Bio-Path Holdings Inc, H2 2017 54
  • Systemic Lupus Erythematosus - Pipeline by Biogen Inc, H2 2017 54
  • Systemic Lupus Erythematosus - Pipeline by Biotest AG, H2 2017 55
  • Systemic Lupus Erythematosus - Pipeline by Boehringer Ingelheim GmbH, H2 2017 55
  • Systemic Lupus Erythematosus - Pipeline by Bristol-Myers Squibb Co, H2 2017 56
  • Systemic Lupus Erythematosus - Pipeline by Celgene Corp, H2 2017 56
  • Systemic Lupus Erythematosus - Pipeline by Corestem Inc, H2 2017 57
  • Systemic Lupus Erythematosus - Pipeline by CuraVac Inc, H2 2017 57
  • Systemic Lupus Erythematosus - Pipeline by Deltanoid Pharmaceuticals Inc, H2 2017 57
  • Systemic Lupus Erythematosus - Pipeline by Domainex Ltd, H2 2017 58
  • Systemic Lupus Erythematosus - Pipeline by Eisai Co Ltd, H2 2017 58
  • Systemic Lupus Erythematosus - Pipeline by Eli Lilly and Co, H2 2017 59
  • Systemic Lupus Erythematosus - Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 59
  • Systemic Lupus Erythematosus - Pipeline by Galapagos NV, H2 2017 60
  • Systemic Lupus Erythematosus - Pipeline by Genentech Inc, H2 2017 60
  • Systemic Lupus Erythematosus - Pipeline by Genosco Inc, H2 2017 61
  • Systemic Lupus Erythematosus - Pipeline by Genovax Srl, H2 2017 61
  • Systemic Lupus Erythematosus - Pipeline by Gilead Sciences Inc, H2 2017 61
  • Systemic Lupus Erythematosus - Pipeline by GlaxoSmithKline Plc, H2 2017 62
  • Systemic Lupus Erythematosus - Pipeline by HanAll Biopharma Co Ltd, H2 2017 62
  • Systemic Lupus Erythematosus - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 63
  • Systemic Lupus Erythematosus - Pipeline by Idorsia Ltd, H2 2017 63
  • Systemic Lupus Erythematosus - Pipeline by Immungenetics AG, H2 2017 64
  • Systemic Lupus Erythematosus - Pipeline by Immunomedics Inc, H2 2017 64
  • Systemic Lupus Erythematosus - Pipeline by Immunwork Inc, H2 2017 65
  • Systemic Lupus Erythematosus - Pipeline by Immupharma Plc, H2 2017 65
  • Systemic Lupus Erythematosus - Pipeline by Invion Ltd, H2 2017 66
  • Systemic Lupus Erythematosus - Pipeline by Janus Biotherapeutics Inc, H2 2017 66
  • Systemic Lupus Erythematosus - Pipeline by Johnson & Johnson, H2 2017 66
  • Systemic Lupus Erythematosus - Pipeline by K-Stemcell Co Ltd, H2 2017 67
  • Systemic Lupus Erythematosus - Pipeline by Karyopharm Therapeutics Inc, H2 2017 67
  • Systemic Lupus Erythematosus - Pipeline by KPI Therapeutics Inc, H2 2017 68
  • Systemic Lupus Erythematosus - Pipeline by Kyowa Hakko Kirin Co Ltd, H2 2017 68
  • Systemic Lupus Erythematosus - Pipeline by Lead Discovery Center GmbH, H2 2017 69
  • Systemic Lupus Erythematosus - Pipeline by LSK BioPartners Inc, H2 2017 69
  • Systemic Lupus Erythematosus - Pipeline by MacroGenics Inc, H2 2017 70
  • Systemic Lupus Erythematosus - Pipeline by MedAnnex Ltd, H2 2017 70
  • Systemic Lupus Erythematosus - Pipeline by Medestea Research & Production SpA, H2 2017 70
  • Systemic Lupus Erythematosus - Pipeline by MedImmune LLC, H2 2017 71
  • Systemic Lupus Erythematosus - Pipeline by Merck & Co Inc, H2 2017 71
  • Systemic Lupus Erythematosus - Pipeline by Merck KGaA, H2 2017 72
  • Systemic Lupus Erythematosus - Pipeline by Millennium Pharmaceuticals Inc, H2 2017 72
  • Systemic Lupus Erythematosus - Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2017 73
  • Systemic Lupus Erythematosus - Pipeline by Mount Tam Biotechnologies Inc, H2 2017 73
  • Systemic Lupus Erythematosus - Pipeline by Nektar Therapeutics, H2 2017 74
  • Systemic Lupus Erythematosus - Pipeline by Neovacs SA, H2 2017 74
  • Systemic Lupus Erythematosus - Pipeline by Nippon Chemiphar Co Ltd, H2 2017 75
  • Systemic Lupus Erythematosus - Pipeline by Novartis AG, H2 2017 75
  • Systemic Lupus Erythematosus - Pipeline by Nuevolution AB, H2 2017 76
  • Systemic Lupus Erythematosus - Pipeline by Omeros Corp, H2 2017 76
  • Systemic Lupus Erythematosus - Pipeline by Pfizer Inc, H2 2017 77
  • Systemic Lupus Erythematosus - Pipeline by Principia Biopharma Inc, H2 2017 77
  • Systemic Lupus Erythematosus - Pipeline by Ra Pharmaceuticals Inc, H2 2017 77
  • Systemic Lupus Erythematosus - Pipeline by RedHill Biopharma Ltd, H2 2017 78
  • Systemic Lupus Erythematosus - Pipeline by Sarepta Therapeutics Inc, H2 2017 78
  • Systemic Lupus Erythematosus - Pipeline by SBI Biotech Co Ltd, H2 2017 79
  • Systemic Lupus Erythematosus - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 79
  • Systemic Lupus Erythematosus - Pipeline by TheraMAB LLC, H2 2017 80
  • Systemic Lupus Erythematosus - Pipeline by TxCell SA, H2 2017 80
  • Systemic Lupus Erythematosus - Pipeline by UCB SA, H2 2017 80
  • Systemic Lupus Erythematosus - Pipeline by Xencor Inc, H2 2017 81
  • Systemic Lupus Erythematosus - Pipeline by XTL Biopharmaceuticals Ltd, H2 2017 81
  • Systemic Lupus Erythematosus - Pipeline by Zai Lab Ltd, H2 2017 82
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 406
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..1), H2 2017 407
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..2), H2 2017 408
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..3), H2 2017 409
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..4), H2 2017 410
  • Systemic Lupus Erythematosus - Dormant Projects, H2 2017 (Contd..5), H2 2017 411
  • Systemic Lupus Erythematosus - Discontinued Products, H2 2017 412
  • Systemic Lupus Erythematosus - Discontinued Products, H2 2017 (Contd..1), H2 2017 413

List of Figures

  • Number of Products under Development for Systemic Lupus Erythematosus, H2 2017 20
  • Number of Products under Development by Companies, H2 2017 21
  • Number of Products under Development by Universities/Institutes, H2 2017 27
  • Number of Products by Top 10 Targets, H2 2017 36
  • Number of Products by Stage and Top 10 Targets, H2 2017 36
  • Number of Products by Top 10 Mechanism of Actions, H2 2017 41
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 41
  • Number of Products by Routes of Administration, H2 2017 46
  • Number of Products by Stage and Routes of Administration, H2 2017 46
  • Number of Products by Top 10 Molecule Types, H2 2017 48
  • Number of Products by Stage and Top 10 Molecule Types, H2 2017 48
Back to Top